Natera Ovarian Cancer Detection Assay



Status:Recruiting
Conditions:Ovarian Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:11/8/2018
Start Date:December 14, 2017
End Date:December 2025
Contact:Sarah D Sawyer, Ph.D.
Email:ssawyer@natera.com
Phone:(650) 249-9090

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Prospective Collection of Samples for Development of the Natera Ovarian Cancer Detection Assay

The purpose of this study is to enroll participants who present with an adnexal mass on
imaging to develop a non-invasive ovarian cancer assay to distinguish between malignant and
benign masses. The study will collect blood, tissue, and health information from these
individuals.


Inclusion Criteria:

- Presenting to clinic with adnexal mass suspicious of ovarian, fallopian tube, or
peritoneal cancer on imaging

- Must be planning surgical resection or biopsy

- Must be treatment naïve

- Must be 18 years or older

- Able to understand and sign a written informed consent document

- Able to provide 40mL of blood (at least 20mL) for each blood draw

Exclusion Criteria:

- Prior removal of either ovary for any reason

- Currently pregnant

- Blood transfusion within 3 months of study enrollment

- History of bone marrow or organ transplant

- Prior history and treatment for any malignancy, with exception of previously treated
non-melanoma skin cancer.

- A medical condition that would place subject at risk as a result of the blood
donation, including but not limited to bleeding disorders, chronic infectious disease,
emphysema or serious anemia
We found this trial at
1
site
Magee-Womens Hospital of UPMC
300 Halket St.
Pittsburgh, Pennsylvania 15213
1-866-MyMagee (696-2433)
Magee-Womens Hospital of UPMC Magee-Womens Hospital of UPMC is a world-class center for both women's...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials